Altimmune
ALT
30 hedge funds and large institutions have $2.18M invested in Altimmune in 2019 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 3 closing their positions.
300% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 3
43% more funds holding
Funds holding: 21 → 30 (+9)
0.41% less ownership
Funds ownership: 7.69% → 7.27% (-0.41%)
11% less capital invested
Capital invested by funds: $2.47M → $2.18M (-$282K)
28% less call options, than puts
Call options by funds: $41K | Put options by funds: $57K
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$121K |
| 2 |
WG
Winton Group
London,
United Kingdom
|
+$118K |
| 3 |
Renaissance Technologies
New York
|
+$96.7K |
| 4 |
Bank of New York Mellon
New York
|
+$95.3K |
| 5 |
VF
Virtu Financial
New York
|
+$67.5K |
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$275K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$62.3K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$55.3K |
| 4 |
D.E. Shaw & Co
New York
|
-$29K |
| 5 |
Squarepoint
New York
|
-$22.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
D.E. Shaw & Co
New York
| – | -$29K | -12,300 | Closed |
|
27
Fidelity Investments
Boston,
Massachusetts
| – | +$2 | +1 | New |
|
|
AIC
28
Ameritas Investment Company
Lincoln,
Nebraska
| – | +$7 | +3 | New |
|
ALT Hedge Fund Activity: Q3 2019 in Review
30 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q3 2019, worth a combined $2.18M — down 11% from $2.47M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ALT positions and 3 closed out — a net gain of 9 holders — while 4 added to existing stakes and 8 trimmed.
The largest buyer was Vanguard Group, adding an estimated $121K. The largest seller was Morgan Stanley, cutting an estimated $275K.
- 30 institutional investors held Altimmune (ALT) as of Q3 2019, up from 21 in Q2 2019.
- Funds reported $2.18M of Altimmune stock for Q3 2019, down 11% quarter-over-quarter.
- 12 funds opened new Altimmune positions in Q3 2019 and 3 closed out, a net change of +9 holders.
- The largest Altimmune buyer in Q3 2019 was Vanguard Group, an estimated $121K added.
- The largest Altimmune seller in Q3 2019 was Morgan Stanley, an estimated $275K sold.
Based on aggregated 13F filings for Q3 2019.